首页> 外文期刊>Clinical nuclear medicine >PSMA Expression in Papillary Thyroid Carcinoma: Opening a New Horizon in Management of Thyroid Cancer?
【24h】

PSMA Expression in Papillary Thyroid Carcinoma: Opening a New Horizon in Management of Thyroid Cancer?

机译:PSMA在乳头状甲状腺癌中的表达:开辟甲状腺癌治疗的新视野?

获取原文
获取原文并翻译 | 示例
           

摘要

Prostate-specific membrane antigen (PSMA) is a type 2 transmembrane protein highly expressed in prostate cancer cells. We present the case of a 50-year-old man with metastatic papillary carcinoma of the thyroid, with rising thyroglobulin level and negative whole-body radioiodine scan after total thyroidectomy. Considering the limited treatment options available, it was decided to perform Ga-68-PSMA-HBED-CC PET/CT scan. It revealed intense radiotracer uptake in mediastinal and left supraclavicular lymph nodes, brain metastases, bilateral lung nodules, and skeletal sites. Patient also underwent F-18-FDG PET/CT. It demonstrated similar findings; however, the number of lesions detected in brain was less compared with Ga-68-PSMA PET/CT.
机译:前列腺特异性膜抗原(PSMA)是在前列腺癌细胞中高度表达的2型跨膜蛋白。我们的病例为一名50岁的甲状腺转移性乳头状癌,甲状腺球蛋白水平升高,全甲状腺切除术后全身放射性碘扫描阴性。考虑到可用的治疗选择有限,因此决定进行Ga-68-PSMA-HBED-CC PET / CT扫描。它显示了纵隔和左锁骨上淋巴结,脑转移,双侧肺结节和骨骼部位中放射性示踪剂的大量摄取。患者还接受了F-18-FDG PET / CT。它显示了类似的发现;然而,与Ga-68-PSMA PET / CT相比,在大脑中检测到的病变数量更少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号